

NET SALES AS OF DECEMBER 31, 2017

Longjumeau, January 31, 2018

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of December 31, 2017.

The PCAS Group had generated consolidated net sales of €218.3 million as of December 31, 2017, representing growth of +13.7% compared to the same period of the previous financial year.

<i>In millions of euros</i>	2017	2016	% change
Net sales as of 31 december	218,3	192,0	13,7%
<i>Pharmaceutical Synthesis</i>	<i>148,9</i>	<i>130,0</i>	<i>14,6%</i>
<i>Fine Specialty Chemicals</i>	<i>69,3</i>	<i>62,0</i>	<i>11,8%</i>

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €148.9 million, up 14.6% on 2016, which was especially driven by the Exclusive activity.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €69.3 million, up 11.8% on 2016, with growth in both Performance Additives and Advanced Specialty Chemicals, more particularly for the micro-electronics part.



NEXT FINANCIAL DISCLOSURE:

2017 results, February 20, 2018

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: www.pcas.com



PCA
LISTED
EURONEXT

PCAS

NewCap

Vincent Touraille / Eric Moissenot
PCAS

Tel. : +33 1 69 79 61 32
www.pcas.com

Emmanuel Huynh / Louis-Victor Delouvier
NewCap
Financial communication and Investor Relations

Tel. : +33 1 44 71 98 53
pcas@newcap.eu